Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for Late-Life Depression
NCT02295787Phase 4Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of ketamine in major depressive disorder (MDD), suicidal ideation, sponsored by Massachusetts General Hospital. Planned start Jul 2015; status: withdrawn.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on NCT02295787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02295787.